Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

SOHO 2020 | Novel antibodies in AML

Marion Subklewe • 26 Aug 2020

SOHO 2020

Acute Myeloid Leukemia Leukemia Antibodies Azacitidine Gemtuzumab ozogamicin Lintuzumab-Ac225 Nivolumab

Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, outlines novel antibody-based immunotherapies developed for the treatment of acute myeloid leukemia (AML), as well as challenges with implementing these agents. Prof. Subklewe also discusses the development of gemtuzumab, the only antibody-drug conjugate approved for the treatment of AML as well as checkpoint inhibitors such as nivolumab, that have been investigated in monotherapy and combination in this indication. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

CD33-TIM3 dual CAR T-cells enhance specificity of AML treatment

Marion Subklewe • 9 Dec 2023

MP0533, a CD3-engaging DARPin, in R/R AML or MDS/AML: preliminary results of a Phase I/IIa trial

Marion Subklewe • 9 Dec 2023

Dose escalation of RO7283420, a HLA-A2-WT1 CD3 T-cell bispecific antibody, in R/R AML

Marion Subklewe • 9 Dec 2023

Novel immunotherapies in AML and insights into the future of the treatment landscape

Marion Subklewe • 9 Dec 2023

Related Videos

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024

Integrating genomics and MRD in transplant decision-making for patients with AML

Jurjen Versluis • 22 Apr 2024

Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL

Alberto Olaya-Vargas • 15 Apr 2024

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024